Alzheimer's Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
Combination therapy with leptin and pioglitazone ameliorates pathologic changes in APP/PS1 mice and may represent a potential treatment approach for AD.
|
29067321 |
2017 |
Alzheimer's Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
The most prevalent non-amnestic cognitive manifestations in participants in the DIAN-OBS cohort were those typical of mild to moderate Alzheimer's disease, including visual agnosia (55·1%, 95% CI 45·7-64·6), aphasia (57·9%, 48·6-67·3), and behavioural changes (61·7%, 51·5-70·0).
|
27777020 |
2016 |
Alzheimer's Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
Leptin, once established as a biomarker, could enhance the understanding of late-onset AD risk over the life course, as well as the clinical progression of prodromal state to manifested AD.
|
26279362 |
2015 |
Alzheimer's Disease
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
These results suggest that leptin levels are intact, but leptin signalling is impaired in AD.
|
25453257 |
2015 |
Alzheimer's Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
We also discuss relevant issues such as the role of leptin, insulin and renin-angiotensin signaling in the brain and the possible role of Wnt signaling in both MS and AD.
|
25084549 |
2014 |
Alzheimer's Disease
|
0.600 |
Therapeutic
|
disease |
RGD |
Amyloid beta lowering and cognition enhancing effects of ghrelin receptor analog [D-Lys (3)] GHRP-6 in rat model of obesity.
|
25296496 |
2014 |
Alzheimer's Disease
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
To determine if measures of adipokines and other blood lipids differentiate between normal controls and persons with Alzheimer's disease (AD), we examined levels of leptin, adiponectin, total cholesterol, high density lipoproteins (HDL), calculated low density lipoproteins (LDL), triglycerides and apolipoprotein E allele status in 148 early AD subjects and 198 normal controls.
|
22232009 |
2012 |
Alzheimer's Disease
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Our study implicates ER stress as the mechanistic link in the 27-OHC-induced negative regulation of leptin, a hormone that has potential therapeutic effects in AD by reducing Aβ and phosphorylated tau accumulation.
|
21983012 |
2012 |
Alzheimer's Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
Leptin, an adipose-derived hormone, promotes neurogenesis in the adult hippocampus, but the way in which this process occurs in the AD brain is still unknown.
|
21335656 |
2011 |
Alzheimer's Disease
|
0.600 |
Therapeutic
|
disease |
CTD_human |
Leptin, an adipocytokine involved in cell survival and in learning, has been demonstrated to regulate Abeta production and tau hyperphosphorylation in transgenic mice for AD.
|
20157255 |
2010 |
Alzheimer's Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
Most strikingly, chronic administration of leptin to AD-transgenic animals reduced the brain Abeta load, underlying its therapeutic potential.
|
15576490 |
2004 |